Less than a tenth of patients that would benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its first guidance on the medications.
Given more than one billion people worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs.
Per estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidance acknowledges that obesity is a long-term condition that can be managed with thorough and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant barriers to broad access to the jabs that can assist patients in reducing substantial weight, says the agency.
Weight-Loss Drug Shortage
Even in the current most optimistic case, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The recommendation encourages countries and companies to increase access, by measures like voluntary licensing.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Injections Function
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people eat less.
People commonly see weight reduction within a few weeks of beginning the regular doses.
Research indicates patients may put most of the weight back on after a year of halting the drug, as their normal hunger resume.
Being above a healthy weight elevates your likelihood for contracting health problems, such as diabetes, heart disease, brain attack, and some cancers.
Obesity affects individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
